P-gp、MRP1、BCRP在晚期NSCLC中的表达及意义

[目的]探讨P-gp、MRP1、BCRP在晚期非小细胞肺癌(NSCLC)中的表达,及其与NSCLC患者临床病理特征及化疗效果的关系。[方法]采用免疫组化SP法检测32例晚期NSCLC患者治疗前肿瘤标本中P-gp、MRP1、BCRP的表达。所有患者接受以铂类为主的化疗方案2个周期,分析P-gp、MRP1、BCRP表达情况与患者临床病理特征及化疗效果的关系。[结果]NSCLC肿瘤中P-gp、MRP1和BCRP阳性表达率分别为46.88%、75.00%和46.88%。腺癌中P-gp表达高于鳞癌;MRP1的表达与年龄有关,60岁以上的患者显示了更高的MRP1表达率。BCRP的表达与化疗效果相关,但P-gp和MRP1的表达与疗效无显著性相关。[结论]BCRP可以作为判断晚期NSCLC患者化疗效果的预测因子。

Expressions of P-glycoprotein, Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein in Advanced Non-small Cell Lung Cancer and Their Significance

[Purpose] To investigate the expression of P-glycoprotein(P-gp), multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP), and the relationship of expression level with clinicopathological features and response to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). [Methods] P-gp, MRP1 and BCRP were detected immunohistochemically in 32 cancer samples from untreated patients with advanced NSCLC who subsequently received platinum-based chemotherapy for 2 cycles. The relationship of P-gp, MRP1 and BCRP expressions with chemotherapeutic response and clinicopathological features were studied. [Results] The positive expression rate of P-gp, MRP1 and BCRP in the NSCLC was 46.88%, 75.00% and 46.88% respectively. P-gp expression in adenocarcinoma was significantly higher than that in squamous cell carcinoma. MRP1 expression related to age. Higher MRP1 expression was found in patients aged over 60. BCRP expression was associated with response to chemotherapy, but no significant associations with P-gp and MRP1 expression. [Conclusion] BCRP may be serve as a predictor for response to chemotherapy in patients with advanced NSCLC.